Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer.

@article{Danesi2003PharmacogeneticsOA,
  title={Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer.},
  author={Romano Danesi and Filippo de Braud and Stefano Fogli and Tommaso Martino de Pas and Antonello Di Paolo and Giuseppe Curigliano and Mario del Tacca},
  journal={Pharmacological reviews},
  year={2003},
  volume={55 1},
  pages={57-103}
}
In mammalian cells, the process of malignant transformation is characterized by the loss or down-regulation of tumor-suppressor genes and/or the mutation or overexpression of proto-oncogenes, whose products promote dysregulated proliferation of cells and extend their life span. Deregulation in intracellular transduction pathways generates mitogenic signals that promote abnormal cell growth and the acquisition of an undifferentiated phenotype. Genetic abnormalities in cancer have been widely… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 289 references

A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC) (Abstract 1228)

  • JP Van Meerbeeck, EF Smit, +4 authors G Giaccone
  • Proc Am Soc Clin Oncol 20:308a
  • 2001
Highly Influential
16 Excerpts

Adenovirusmediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study

  • M Schuler, R Herrmann, +15 authors C Rochlitz
  • 2001
Highly Influential
10 Excerpts

Similar Papers

Loading similar papers…